ZYMENasdaqPharmaceutical PreparationsFiscal year ends December 31
Zymeworks Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$25.54+0.51 (+2.04%)
Close on Oct 19, 2026
- Market cap
- $1.86B
- P/E (TTM)
- –
- Dividend yield
- –
Zymeworks statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Zymeworks | Industry median |
|---|---|---|
| Market Cap | $1.81B | $197.05M |
| Enterprise Value | $1.63B | $106.56M |
| PS Ratio | 48.81 | 3.93 |
| PB Ratio | 22.55 | 2.14 |
| P/TBV Ratio | 26.91 | 2.46 |
Enterprise value
| Measure | Zymeworks | Industry median |
|---|---|---|
| EV / Sales | 43.98 | 2.69 |
Income (trailing twelve months)
| Measure | Zymeworks | Industry median |
|---|---|---|
| Revenue | $37.13M | $57.94M |
| Operating Income | -$155.56M | -$21.44M |
| Pretax Income | -$151.39M | -$14.45M |
| Net Income | -$149.99M | -$22.46M |
| EBITDA | -$155.56M | -$16.91M |
| EPS (Diluted) | -$2.02 | -$0.83 |
Margins
| Measure | Zymeworks | Industry median |
|---|---|---|
| Operating Margin | -419.0% | -44.5% |
| Pretax Margin | -407.8% | -13.0% |
| Profit Margin | -404.0% | -39.2% |
| EBITDA Margin | -419.0% | -31.3% |
| FCF Margin | -324.7% | -8.85% |
Returns
| Measure | Zymeworks | Industry median |
|---|---|---|
| Return on Equity (ROE) | -72.3% | -53.1% |
| Return on Assets (ROA) | -37.2% | -41.0% |
| Return on Invested Capital (ROIC) | -179.1% | -32.0% |
| Return on Capital Employed (ROCE) | -44.5% | -37.8% |
Growth
| Measure | Zymeworks | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -69.8% | 6.01% |
| Revenue Growth (3Y CAGR) | -36.4% | 2.25% |
| Revenue Growth (5Y CAGR) | 22.2% | 6.42% |
Balance sheet
| Measure | Zymeworks | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $179.41M | $62.42M |
| Net Cash (Debt) | $179.41M | $15.68M |
| Net Cash Per Share | $2.53 | $0.65 |
| Equity (Book Value) | $80.37M | $48.79M |
| Book Value Per Share | $1.13 | $1.36 |
| Tangible Book Value | $67.36M | $23.06M |
| Working Capital | $251.15M | $75.77M |
Financial position
| Measure | Zymeworks | Industry median |
|---|---|---|
| Current Ratio | 6.32 | 3.30 |
| Quick Ratio | 3.92 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Zymeworks | Industry median |
|---|---|---|
| Operating Cash Flow | -$119.34M | -$12.35M |
| Capital Expenditures | -$1.21M | -$1.06M |
| Free Cash Flow | -$120.54M | -$20.28M |
| FCF Per Share | -$1.70 | -$0.41 |
Efficiency
| Measure | Zymeworks | Industry median |
|---|---|---|
| Asset Turnover | 0.09 | 0.38 |
| Revenue Per Employee | $140.63K | $398.96K |
| Profits Per Employee | -$568.15K | -$732.08K |
| Employee Count | 264 | 73 |
Dividends and yields
| Measure | Zymeworks | Industry median |
|---|---|---|
| Earnings Yield | -8.28% | -21.2% |
| FCF Yield | -6.65% | -7.64% |
| Buyback Yield | 9.37% | -0.58% |
| Shareholder Yield | 9.37% | 0.00% |
Shares
| Measure | Zymeworks | Industry median |
|---|---|---|
| Shares Outstanding | 70,959,200 | 59,128,900 |
| Shares Change (YoY) | -1.54% | 11.1% |
| Shares Change (QoQ) | -2.31% | 0.54% |
| Float | 29,175,100 | 48,744,500 |
| Shares Held by Insiders | 58.9% | 11.8% |
| Shares Held by Institutions | 98.1% | 59.4% |
Taxes
| Measure | Zymeworks | Industry median |
|---|---|---|
| Income Tax | -$1.40M | $91.50K |
Scores
| Measure | Zymeworks | Industry median |
|---|---|---|
| Altman Z-Score | -1.14 | 0.10 |
| Piotroski F-Score | 6 | 4 |
Calculated by StockData from Zymeworks's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.